|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
WO2002010379A2
(en)
*
|
2000-07-31 |
2002-02-07 |
Aventis Pasteur Limited |
Modified cea and uses thereof
|
|
WO2001024832A2
(de)
*
|
1999-09-27 |
2001-04-12 |
Gabriele Pecher |
Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
|
|
CA2388301C
(en)
*
|
1999-10-22 |
2011-01-04 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7449557B2
(en)
|
2000-06-02 |
2008-11-11 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
US7025968B2
(en)
|
2000-08-30 |
2006-04-11 |
Chemocentryx, Inc. |
CMV vaccines
|
|
WO2002027007A2
(en)
|
2000-09-25 |
2002-04-04 |
Regents Of The University Of Michigan |
Production of viral vectors
|
|
CA2437201C
(en)
|
2001-02-02 |
2008-11-18 |
Chemocentryx, Inc. |
Methods and compositions useful for stimulating an immune response
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
|
WO2005035773A2
(en)
*
|
2003-10-08 |
2005-04-21 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
|
JP4914990B2
(ja)
|
2002-12-16 |
2012-04-11 |
グローブイミューン，インコーポレイテッド |
動物を癌から守るための治療用組成物
|
|
AU2004273034A1
(en)
*
|
2003-09-05 |
2005-03-24 |
Sanofi Pasteur Limited |
Multi-antigen vectors for melanoma
|
|
WO2005046622A2
(en)
|
2003-11-12 |
2005-05-26 |
Therion Biologics Corporation |
Custom vectors for treating and preventing pancreatic cancer
|
|
ES2476990T3
(es)
*
|
2003-11-12 |
2014-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sistema para tratar y prevenir cáncer de mama
|
|
US20090156519A1
(en)
*
|
2003-12-23 |
2009-06-18 |
Aventis Pasteur, Inc. |
Modified KSA and Uses Thereof
|
|
CN1976946A
(zh)
*
|
2004-07-03 |
2007-06-06 |
财团法人牧岩生命工学研究所 |
诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用
|
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
|
US8389282B2
(en)
*
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
|
ES2608604T3
(es)
*
|
2007-10-18 |
2017-04-12 |
Bavarian Nordic A/S |
Uso de MVA para tratar el cáncer de próstata
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
JP5588990B2
(ja)
*
|
2008-10-31 |
2014-09-10 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
ES2660597T3
(es)
|
2009-04-17 |
2018-03-23 |
Globeimmune, Inc. |
Composiciones inmunoterápicas de combinación contra el cáncer y métodos
|
|
CN109010809A
(zh)
|
2011-08-17 |
2018-12-18 |
全球免疫股份有限公司 |
酵母-muc1免疫治疗组合物及其用途
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
SG11201510064WA
(en)
|
2013-06-14 |
2016-01-28 |
Psioxus Theraupeutics Ltd |
A dosing regime and formulations for type b adenoviruses
|
|
KR102272932B1
(ko)
|
2013-10-25 |
2021-07-05 |
싸이오서스 테라퓨틱스 엘티디. |
이종 유전자로 무장된 종양살상 아데노바이러스
|
|
ES2895977T3
(es)
*
|
2013-11-28 |
2022-02-23 |
Bavarian Nordic As |
Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
|
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
AU2016205215B2
(en)
|
2015-01-09 |
2021-03-11 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
US10695417B2
(en)
|
2015-01-09 |
2020-06-30 |
Etubics Corporation |
Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
DK3288573T3
(da)
|
2015-04-30 |
2020-03-16 |
Psioxus Therapeutics Ltd |
Onkolytisk adenovirus, der koder for et b7-protein
|
|
US11155622B2
(en)
|
2015-12-17 |
2021-10-26 |
Psioxus Therapeutics Limited |
Virus encoding an anti-TCR-complex antibody or fragment
|
|
AU2017233072B2
(en)
*
|
2016-03-18 |
2020-12-24 |
Nantcell, Inc. |
Multimodal vector for dendritic cell infection
|
|
EP3735984A1
(en)
*
|
2016-05-27 |
2020-11-11 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
|
KR102491752B1
(ko)
|
2016-08-29 |
2023-01-26 |
싸이오서스 테라퓨틱스 엘티디. |
이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
CA3092860A1
(en)
*
|
2018-03-06 |
2019-09-12 |
Pepvax, Inc. |
Nucleic acid molecules and methods of using the same
|
|
US20210290708A1
(en)
|
2018-09-21 |
2021-09-23 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
GB202010095D0
(en)
*
|
2020-07-01 |
2020-08-12 |
Tcer Ab |
Immunotherapy
|